Back to top

Guardant Health stock climbs as investors continue to digest screening and diagnostics catalysts

Guardant Health (GH) is up 6.8% today. Here is some analysis on what might have caused this price movement. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Reports-First-Quarter-2026-Financial-Results-and-Increases-2026-Revenue-Guidance/default.aspx?utm_source=openai))

Analysis: There does not appear to be a single fresh company announcement driving the move today, so the gain likely reflects continued investor enthusiasm around several recent catalysts. The biggest positives have been Guardant Health’s raised 2026 revenue outlook, the inclusion of its Shield blood test in updated colorectal cancer screening guidance, and a new FDA approval that expanded the capabilities of its Guardant360 liquid biopsy platform. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Reports-First-Quarter-2026-Financial-Results-and-Increases-2026-Revenue-Guidance/default.aspx?utm_source=openai))

Details:

  • Guardant Health reported first-quarter 2026 results in May and increased its full-year 2026 revenue guidance, giving investors a more constructive view of near-term growth. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Reports-First-Quarter-2026-Financial-Results-and-Increases-2026-Revenue-Guidance/default.aspx?utm_source=openai))
  • The American Cancer Society updated its colorectal cancer screening guidelines in late May to include Guardant Health’s Shield blood test for average-risk adults 45 and older who decline or have not completed other recommended screening options. ([nasdaq.com](https://www.nasdaq.com/press-release/american-cancer-society-recommends-guardant-healths-shield-blood-test-updated?utm_source=openai))
  • The FDA approved Guardant360 Liquid CDx in May, and Guardant Health said the test has a much broader genomic footprint than the earlier version, which can strengthen its position in precision oncology diagnostics. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/FDA-Approves-New-Guardant360-Liquid-CDx-the-Largest-FDA-Approved-Liquid-Biopsy-Panel-with-a-100x-Expanded-Footprint/default.aspx?utm_source=openai))
  • Guardant Health also said Shield is available through a broad national ordering and collection network, which supports the longer-term commercialization story for its screening business. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Healths-Shield-Blood-based-Screening-Test-for-Colorectal-Cancer-Now-Accessible-Through-National-Test-Ordering-and-Collection-Network-of-Quest-Diagnostics/default.aspx?utm_source=openai))

    • Sources:

    Guardant Health Investor Relations, Nasdaq, Stock Analysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $GH Insider Trading Activity

    GH Insider Trades

    $GH insiders have traded $GH stock on the open market 56 times in the past 6 months. Of those trades, 0 have been purchases and 56 have been sales.

    Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

    • AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 13 sales selling 260,000 shares for an estimated $28,092,690.
    • HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 7 sales selling 100,000 shares for an estimated $12,629,968.
    • KUMUD KALIA (Chief Information Officer) has made 0 purchases and 4 sales selling 48,418 shares for an estimated $4,909,846.
    • JOHN G. SAIA (Chief Legal Officer) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $3,381,064.
    • CHRIS FREEMAN (Chief Commercial Officer) sold 24,406 shares for an estimated $2,896,360
    • TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 7 sales selling 22,434 shares for an estimated $2,457,331.
    • MEGHAN V. JOYCE has made 0 purchases and 4 sales selling 10,000 shares for an estimated $1,269,808.
    • STEVE E. KROGNES sold 9,294 shares for an estimated $1,231,521
    • IAN T CLARK sold 6,876 shares for an estimated $735,048
    • MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,000 shares for an estimated $518,351.
    • MEDINA MANUEL HIDALGO has made 0 purchases and 5 sales selling 3,550 shares for an estimated $382,920.
    • MUSA TARIQ has made 0 purchases and 5 sales selling 2,647 shares for an estimated $322,622.
    • MYRTLE S POTTER sold 1,556 shares for an estimated $204,084

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $GH Hedge Fund Activity

    We have seen 262 institutional investors add shares of $GH stock to their portfolio, and 251 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $GH Analyst Ratings

    Wall Street analysts have issued reports on $GH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • BTIG issued a "Buy" rating on 02/20/2026

    To track analyst ratings and price targets for $GH, check out Quiver Quantitative's $GH forecast page.

    $GH Price Targets

    Multiple analysts have issued price targets for $GH recently. We have seen 18 analysts offer price targets for $GH in the last 6 months, with a median target of $142.5.

    Here are some recent targets:

    • Luke Sergott from Barclays set a target price of $150.0 on 06/24/2026
    • Dan Leonard from RBC Capital set a target price of $185.0 on 06/11/2026
    • Anthony Petrone from Mizuho set a target price of $175.0 on 06/08/2026
    • Evie Koslosky from Goldman Sachs set a target price of $165.0 on 06/05/2026
    • Vijay Kumar from Evercore ISI Group set a target price of $160.0 on 06/02/2026
    • Mike Polark from Wolfe Research set a target price of $150.0 on 06/02/2026
    • Mark Massaro from BTIG set a target price of $160.0 on 05/27/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Read full article here »

    In-Depth Zacks Research for the Tickers Above

    Normally $25 each - click below to receive one report FREE:

    Guardant Health, Inc. (GH)